[CIMB] QoQ TTM Result on 30-Sep-2022 [#3]

Announcement Date
30-Nov-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Sep-2022 [#3]
Profit Trend
QoQ- 43.56%
YoY- 35.93%
View:
Show?
TTM Result
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Revenue 20,547,976 20,098,392 19,837,516 19,204,516 18,603,156 18,389,416 19,609,712 3.17%
PBT 8,936,408 8,559,733 8,371,010 7,335,630 5,466,547 4,939,405 5,789,478 33.66%
Tax -2,624,208 -2,744,564 -2,778,079 -2,216,187 -1,868,827 -1,554,262 -1,396,853 52.42%
NP 6,312,200 5,815,169 5,592,931 5,119,443 3,597,720 3,385,143 4,392,625 27.42%
-
NP to SH 6,150,182 5,657,789 5,439,863 4,969,422 3,461,597 3,265,085 4,295,334 27.11%
-
Tax Rate 29.37% 32.06% 33.19% 30.21% 34.19% 31.47% 24.13% -
Total Cost 14,235,776 14,283,223 14,244,585 14,085,073 15,005,436 15,004,273 15,217,087 -4.35%
-
Net Worth 66,992,836 65,326,948 62,114,290 61,855,700 59,906,296 59,787,314 58,500,021 9.48%
Dividend
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Div 3,244,496 2,730,366 2,730,366 2,627,138 2,627,138 2,318,053 2,318,053 25.20%
Div Payout % 52.75% 48.26% 50.19% 52.87% 75.89% 71.00% 53.97% -
Equity
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Net Worth 66,992,836 65,326,948 62,114,290 61,855,700 59,906,296 59,787,314 58,500,021 9.48%
NOSH 10,665,106 10,665,106 10,665,106 10,474,258 10,474,258 10,221,456 10,221,456 2.88%
Ratio Analysis
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
NP Margin 30.72% 28.93% 28.19% 26.66% 19.34% 18.41% 22.40% -
ROE 9.18% 8.66% 8.76% 8.03% 5.78% 5.46% 7.34% -
Per Share
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 192.67 188.45 187.13 183.35 178.84 179.91 193.04 -0.12%
EPS 57.67 53.05 51.32 47.44 33.28 31.94 42.28 23.06%
DPS 30.50 25.60 25.76 25.08 25.26 22.68 22.82 21.40%
NAPS 6.2815 6.1253 5.8594 5.9055 5.7591 5.8492 5.7588 5.97%
Adjusted Per Share Value based on latest NOSH - 10,474,258
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
RPS 192.06 187.86 185.42 179.50 173.88 171.88 183.29 3.17%
EPS 57.49 52.88 50.85 46.45 32.36 30.52 40.15 27.12%
DPS 30.33 25.52 25.52 24.56 24.56 21.67 21.67 25.20%
NAPS 6.2618 6.106 5.8058 5.7816 5.5994 5.5883 5.4679 9.48%
Price Multiplier on Financial Quarter End Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 -
Price 5.06 5.31 5.80 5.13 4.96 5.33 5.45 -
P/RPS 2.63 2.82 3.10 2.80 2.77 2.96 2.82 -4.55%
P/EPS 8.77 10.01 11.30 10.81 14.90 16.69 12.89 -22.69%
EY 11.40 9.99 8.85 9.25 6.71 5.99 7.76 29.32%
DY 6.03 4.82 4.44 4.89 5.09 4.25 4.19 27.55%
P/NAPS 0.81 0.87 0.99 0.87 0.86 0.91 0.95 -10.10%
Price Multiplier on Announcement Date
30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 CAGR
Date 30/08/23 31/05/23 28/02/23 30/11/22 30/08/22 31/05/22 28/02/22 -
Price 5.63 4.82 5.61 5.80 5.37 5.15 5.71 -
P/RPS 2.92 2.56 3.00 3.16 3.00 2.86 2.96 -0.90%
P/EPS 9.76 9.09 10.93 12.22 16.14 16.12 13.50 -19.49%
EY 10.24 11.01 9.15 8.18 6.20 6.20 7.41 24.14%
DY 5.42 5.31 4.59 4.32 4.70 4.40 4.00 22.51%
P/NAPS 0.90 0.79 0.96 0.98 0.93 0.88 0.99 -6.17%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment